Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
94zMr5KBp9aSNzpk
Listen
